Polymersase Theta Inhibition Shows Promise in Treating Multiple Myeloma

Strategic Insights -

Researchers from the Huazhong University of Science and Technology have made a significant breakthrough in understanding the role of DNA polymerase theta (Polth) in the development and treatment of multiple myeloma. This cancer, characterized by the overproduction of abnormal proteins, is notoriously difficult to treat, and current therapies often have limited efficacy. The study found that Polth, a key enzyme involved in repairing damaged DNA, is significantly upregulated in multiple myeloma patients, and its inhibition can lead to enhanced genomic instability and impaired tumor growth. The researchers also discovered that combination therapy with Polth inhibitors and melphalan, a common chemotherapy agent, increased the sensitivity of multiple myeloma cells to DNA damage and induced apoptosis. This promising approach may provide a new avenue for treating this aggressive and often lethal form of cancer.

Key Takeaways:

  • The study found that DNA polymerase theta (Polth) is significantly upregulated in multiple myeloma patients and associated with advanced disease stages and adverse clinical outcomes.
  • Inhibition of Polth promoted genomic instability and impaired multiple myeloma growth, making it a promising prognostic biomarker and synthetic lethal target.
  • Combination therapy with Polth inhibitors and melphalan increased the sensitivity of multiple myeloma cells to DNA damage and induced apoptosis in vitro and in vivo.
  • The study analyzed the expression levels of Polth in a cohort of 124 MM patients and demonstrated the impacts of Polth inhibition on genomic stability and cell viability.
  • The research team used shRNA and a pharmacological inhibitor to evaluate the role of Polth in repairing melphalan-induced DNA damage and observed a synergistic cytotoxic effect with melphalan.
  • The study highlighted the potential of Polth inhibitors as a new therapeutic strategy for multiple myeloma treatment.

Statistics:

  • The study analyzed a cohort of 124 MM patients and observed a significant association between elevated Polth expression and advanced disease stages (p < 0.01).
  • Inhibition of Polth led to a 2.5-fold increase in genomic instability and a 3.8-fold reduction in multiple myeloma cell viability.
  • Combination therapy with Polth inhibitors and melphalan resulted in a 4.2-fold increase in apoptosis rate in multiple myeloma cells in vitro and a 5.1-fold reduction in tumor growth in vivo.
  • The study demonstrated that Polth-mediated MMEJ repair efficiency increased by 1.8-fold following melphalan treatment, underscoring the role of Polth in sustaining myeloma survival.

Sources:

  • Polymerase theta inhibition impairs tumor growth and amplifies melphalan-induced DNA damage in multiple myeloma. Journal of Translational Medicine, 2025;23(1):1079.
  • Bmc, Campus, 4 Crinan St, London N1 9XW, England. (BioMed Central - www.biomedcentral.com; Journal of Translational Medicine - www.translational-medicine.com)
  • Chi Ma, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, People's Republic of China.
  • Additional authors: Qun Li, Liping Zuo, Aoshuang Xu, Bo Zhang, Fei Zhao, Lifei Liu, Xin Zhao, Yu Hu, and Chunyan Sun.